Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study
Objective. Intrahepatic cholestasis of pregnancy (ICP) is a common pregnancy-related liver disease and is associated with an increased risk of adverse neonatal outcomes. Ursodeoxycholic acid (UDCA) is the most effective treatment. This study was aimed at investigating the adverse outcomes of ICP and...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/6641023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550896585670656 |
|---|---|
| author | Mingjuan Luo Mengyang Tang Feng Jiang Yizhen Jia Robert Kien Howe Chin Wei Liang Hu Cheng |
| author_facet | Mingjuan Luo Mengyang Tang Feng Jiang Yizhen Jia Robert Kien Howe Chin Wei Liang Hu Cheng |
| author_sort | Mingjuan Luo |
| collection | DOAJ |
| description | Objective. Intrahepatic cholestasis of pregnancy (ICP) is a common pregnancy-related liver disease and is associated with an increased risk of adverse neonatal outcomes. Ursodeoxycholic acid (UDCA) is the most effective treatment. This study was aimed at investigating the adverse outcomes of ICP and evaluating the effects of treatment with UDCA in patients with ICP. Methods. We included 114 women with ICP and 3725 women without ICP (no-ICP group) who delivered in our hospital between September 2017 and August 2019. The prevalence of ICP in this study was 3.15%. We matched each woman with ICP to five controls. Of all the 114 women with ICP, 73 (64.04%) received UDCA while 41 (35.96%) did not. Logistic multivariate regression analysis was used to compare the adverse outcomes between those with ICP and matched controls as well as between those who received UDCA (UDCA group) and those who did not (non-UDCA group). Results. Compared with controls, women with ICP were more likely to have preeclampsia (adjusted odds ratio, aOR=16.74, 95% CI 5.29–52.98), cesarean section (aOR=1.76, 95% CI 1.10–2.81), and preterm birth (aOR=24.35, 95% CI 2.74–216.67). Administration of UDCA reduced the rate of preterm birth (1.37% vs. 14.63%, aOR=0.10, 95% CI 0.01–0.90). Conclusion. ICP increased the risk of preeclampsia, cesarean section, and preterm birth. UDCA could reduce the rate of preterm birth. |
| format | Article |
| id | doaj-art-3ea17ad496bd4eb1ade772a55865e388 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-3ea17ad496bd4eb1ade772a55865e3882025-02-03T06:05:27ZengWileyGastroenterology Research and Practice1687-61211687-630X2021-01-01202110.1155/2021/66410236641023Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control StudyMingjuan Luo0Mengyang Tang1Feng Jiang2Yizhen Jia3Robert Kien Howe Chin4Wei Liang5Hu Cheng6The Third School of Clinical Medicine, Southern Medical University, Guangzhou, 510000 Guangdong, ChinaThe Third School of Clinical Medicine, Southern Medical University, Guangzhou, 510000 Guangdong, ChinaShanghai Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, ChinaCore Laboratory, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053 Guangdong, ChinaDepartment of Obstetrics and Gynecology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053 Guangdong, ChinaDepartment of Endocrinology and Metabolism, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053 Guangdong, ChinaThe Third School of Clinical Medicine, Southern Medical University, Guangzhou, 510000 Guangdong, ChinaObjective. Intrahepatic cholestasis of pregnancy (ICP) is a common pregnancy-related liver disease and is associated with an increased risk of adverse neonatal outcomes. Ursodeoxycholic acid (UDCA) is the most effective treatment. This study was aimed at investigating the adverse outcomes of ICP and evaluating the effects of treatment with UDCA in patients with ICP. Methods. We included 114 women with ICP and 3725 women without ICP (no-ICP group) who delivered in our hospital between September 2017 and August 2019. The prevalence of ICP in this study was 3.15%. We matched each woman with ICP to five controls. Of all the 114 women with ICP, 73 (64.04%) received UDCA while 41 (35.96%) did not. Logistic multivariate regression analysis was used to compare the adverse outcomes between those with ICP and matched controls as well as between those who received UDCA (UDCA group) and those who did not (non-UDCA group). Results. Compared with controls, women with ICP were more likely to have preeclampsia (adjusted odds ratio, aOR=16.74, 95% CI 5.29–52.98), cesarean section (aOR=1.76, 95% CI 1.10–2.81), and preterm birth (aOR=24.35, 95% CI 2.74–216.67). Administration of UDCA reduced the rate of preterm birth (1.37% vs. 14.63%, aOR=0.10, 95% CI 0.01–0.90). Conclusion. ICP increased the risk of preeclampsia, cesarean section, and preterm birth. UDCA could reduce the rate of preterm birth.http://dx.doi.org/10.1155/2021/6641023 |
| spellingShingle | Mingjuan Luo Mengyang Tang Feng Jiang Yizhen Jia Robert Kien Howe Chin Wei Liang Hu Cheng Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study Gastroenterology Research and Practice |
| title | Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study |
| title_full | Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study |
| title_fullStr | Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study |
| title_full_unstemmed | Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study |
| title_short | Intrahepatic Cholestasis of Pregnancy and Associated Adverse Maternal and Fetal Outcomes: A Retrospective Case-Control Study |
| title_sort | intrahepatic cholestasis of pregnancy and associated adverse maternal and fetal outcomes a retrospective case control study |
| url | http://dx.doi.org/10.1155/2021/6641023 |
| work_keys_str_mv | AT mingjuanluo intrahepaticcholestasisofpregnancyandassociatedadversematernalandfetaloutcomesaretrospectivecasecontrolstudy AT mengyangtang intrahepaticcholestasisofpregnancyandassociatedadversematernalandfetaloutcomesaretrospectivecasecontrolstudy AT fengjiang intrahepaticcholestasisofpregnancyandassociatedadversematernalandfetaloutcomesaretrospectivecasecontrolstudy AT yizhenjia intrahepaticcholestasisofpregnancyandassociatedadversematernalandfetaloutcomesaretrospectivecasecontrolstudy AT robertkienhowechin intrahepaticcholestasisofpregnancyandassociatedadversematernalandfetaloutcomesaretrospectivecasecontrolstudy AT weiliang intrahepaticcholestasisofpregnancyandassociatedadversematernalandfetaloutcomesaretrospectivecasecontrolstudy AT hucheng intrahepaticcholestasisofpregnancyandassociatedadversematernalandfetaloutcomesaretrospectivecasecontrolstudy |